{"id":13257,"date":"2024-08-23T02:36:55","date_gmt":"2024-08-23T00:36:55","guid":{"rendered":"https:\/\/valintermed.com\/?p=13257"},"modified":"2024-08-23T02:36:55","modified_gmt":"2024-08-23T00:36:55","slug":"tromboticheskaya-trombotsitopenicheskaya-purpura","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/thrombotic-thrombotic-spondylitis\/","title":{"rendered":"Thrombotic thrombocytopenic purpura"},"content":{"rendered":"
<\/div>\n

Thrombotic thrombocytopenic purpura (TTP) is a rare but serious disorder characterized by a blood clotting disorder that leads to the formation of blood clots in microvessels and a decrease in platelet levels. This condition is primarily associated with abnormal activity of the enzyme ADAMTS13, which is responsible for the degradation of von Willebrand factor multimers, which leads to their accumulation and formation of blood clots. The main manifestations of the disease are purpura (skin hemorrhages), anemia, thrombocytopenia and signs of organ damage, which can lead to serious complications, including death, if not treated promptly. TTP can be either primary (hereditary) or secondary, developing as a result of various provoking factors, including infections, pregnancy and some tumors.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n